Plaque-stabilizing therapy
Apoptosis has a recognized role in locating atherosclerotic plaques at risk of rupture. Conjugating effective plaque stabilizing agents to Aposense probes can promote targeted delivery of such therapies to critical arterial lesions that are prone to rupture in high-risk patients.
Myocardial infarct and cerebral ischemic stroke
The role of apoptosis in acute ischemic myocardial or cerebral infarct is widely understood. During restoration of blood flow to the ischemic region in the heart or brain, a secondary process of delayed cell death in the surrounding cells starts to take place, even in areas that are distant from the ischemic core, which may also occur a good while after the acute injury. This is an unavoidable consequence of successful reperfusion, and yet a common cause of additional damage.
Targeted delivery of a protective agent, directed at the apoptotic tissue associated with the reperfusion injury, may inhibit this secondary death process and improve patient outcome.
[18F]-ML-10 is an investigational agent, not yet approved for use outside clinical trials